

CONTENTS

Advances in Brief

- 265 Endothelial Cell Vehicles for Delivery of Cytotoxic Genes as a Gene Therapy Approach for Carcinoma of the Ovary.** Claudine Rancourt, Matthew W. Robertson III, Minghui Wang, Corey K. Goldman, Joseph F. Kelly, Ronald D. Alvarez, Gene P. Siegal, and David T. Curiel.
- 271 A Prospective Study of K-ras Mutations in the Plasma of Pancreatic Cancer Patients.** Hugh E. Mulcahy, Jacqueline Lyautey, Christine Lederrey, Xu qi Chen, Philippe Anker, Elspeth M. Alstead, Anne Ballinger, Michael J. G. Farthing, and Maurice Stroun.

Research Articles

- 277 Pharmacodynamics of Doxorubicin in Human Prostate Tumors.** Chiung-Tong Chen, Jessie L-S. Au, and M. Guillaume Wientjes.
- 283 Phase II Trial of Sequential Radiation and Interleukin 2 in the Treatment of Patients with Metastatic Renal Cell Carcinoma.** Bruce G. Redman, Gilda G. Hillman, Lawrence Flaherty, Jeffrey Forman, Balazs Dezso, and Gabriel P. Haas.
- 287 RET/PTC Oncogene Activation Defines a Subset of Papillary Thyroid Carcinomas Lacking Evidence of Progression to Poorly Differentiated or Undifferentiated Tumor Phenotypes.** Giovanni Tallini, Massimo Santoro, Mary Helie, Francesca Carlomagno, Giuliana Salvatore, Gennaro Chiappetta, Maria Luisa Carcangiu, and Alfredo Fusco.
- 295 Expression of Potential Target Antigens for Immunotherapy on Primary and Metastatic Prostate Cancers.** Shengle Zhang, Helen S. Zhang, Victor E. Reuter, Susan F. Slovin, Howard I. Scher, and Philip O. Livingston.
- 303 Phase I Dose De-escalation Trial of α -Difluoromethylornithine in Patients with Grade 3 Cervical Intraepithelial Neoplasia.** Michele Follen Mitchell, Guillermo Tortolero-Luna, J. Jack Lee, Walter N. Hittelman, Reuben Lotan, J. Taylor Wharton, Waun K. Hong, and Kenji Nishioka.
- 311 Factors Affecting Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma.** Craig H. Moskowitz, Jill R. Glassman, David Wuest, Peter Maslak, Lilian Reich, Anthony Gucciardo, Nancy Coody-Lyons, Andrew D. Zelenetz, and Stephen D. Nimer.
- 317 Phase I Trial of the Colloidal Dispersion Formulation of 9-Amino-20(S)-camptothecin Administered as a 72-Hour Continuous Intravenous Infusion.** Joseph P. Eder, Jr., Jeffrey G. Supko, Thomas Lynch, Margaret Bryant, Evan Vosburgh, Lawrence N. Shulman, Guangxin Xu, and Donald W. Kufe.
- 325 Decreased Dihydropyrimidine Dehydrogenase Activity in a Population of Patients with Breast Cancer: Implication for 5-Fluorouracil-based Chemotherapy.** Zhihong Lu, Ruiwen Zhang, John T. Carpenter, and Robert B. Diasio.
- 331 Influence of Amifostine on the Pharmacokinetics of Cisplatin in Cancer Patients.** Annelies E. C. Korst, Marianne L. T. van der Sterre, Helen E. Gall, Anne Marie J. Fichtinger-Schepman, Jan B. Vermorken, and Wim J. F. van der Vijgh.
- 337 Quantitation of DNA from Exfoliated Colonocytes Isolated from Human Stool Surface as a Novel Noninvasive Screening Test for Colorectal Cancer.** Alexandre Loktionov, Ian K. O'Neill, Katharine R. Silvester, John H. Cummings, Steve J. Middleton, and Richard Miller.
- 343 Dissemination of Tumor Cells in Patients Undergoing Surgery for Colorectal Cancer.** Jürgen Weitz, Peter Kienle, Jeannine Lacroix, Frank Willeke, Axel Benner, Thomas Lehnert, Christian Herfarth, and Magnus von Knebel Doeberitz.
- 349 Sequence-dependent Hematological Toxicity Associated with the 3-Hour Paclitaxel/Cyclophosphamide Doublet.** M. John Kennedy, Marianna L. Zahurak, Ross C. Donehower, Dennis Noe, Louise B. Grochow, Susan Sartorius, Tian-Ling Chen, Kathy Bowling, Mary Duerr, and Eric K. Rowinsky.
- 357 Phase II Trial of Topotecan Administered as a 72-Hour Continuous Infusion in Children with Refractory Solid Tumors: A Collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.** Susan M. Blaney, Michael N. Needle, Andy Gillespie, Judith K. Sato, Gregory H. Reaman, Stacey L. Berg, Peter C. Adamson, Mark D. Krailo, W. Archie Bleyer, David G. Poplack, and Frank M. Balis.
- 361 Frequent Detection of ras and p53 Mutations in Brush Cytology Samples from Lung Cancer Patients by a Restriction Fragment Length Polymorphism-based "Enriched PCR" Technique.** Moira Behn, Shen Qun, Wulf Pankow, Klaus Havemann, and Marcus Schuermann.
- 373 The Relationship between Concentrations of Circulating Soluble E-Selectin and Clinical, Pathological, and Biological Features in Patients with Breast Cancer.** Mohamed Hebbar, Françoise Révillion, Marie-Michèle Louchez, Marie-Odile Vilain, Charles Fournier, Jacques Bonnetterre, and Jean-Philippe Peyrat.
- 381 Reduced Expression of Interleukin 6 in Undifferentiated Thyroid Carcinoma: *In Vitro* and *In Vivo* Studies.** Fulvio Basolo, Lisa Fiore, Luca Pollina, Gabriella Fontanini, Pier Giulio Conaldi, and Antonio Toniolo.
- 389 Levels of Multidrug Resistance (MDR1) P-Glycoprotein Expression by Human Breast Cancer Correlate with *In Vitro* Resistance to Taxol and Doxorubicin.** Eugene Mechetner, Ainura Kyshtoobayeva, Svetlana Zonis, Hun Kim, Robert Stroup, Roxanna Garcia, Ricardo J. Parker, and John P. Fruehauf.
- 399 Quantitative Differences in Telomerase Activity among Malignant, Premalignant, and Benign Ovarian Lesions.** Satoru Kyo, Masahiro Takakura, Masaaki Tanaka, Koichi Murakami, Rie Saitoh, Hisao Hirano, and Masaki Inoue.

- 407 **Prognostic Value of $\alpha 6\beta 4$ Integrin Expression in Breast Carcinomas Is Affected by Laminin Production from Tumor Cells.** Elda Tagliabue, Cristina Ghirelli, Paolo Squicciarini, Pierangela Aiello, Maria Ines Colnaghi, and Sylvie Ménard.
- 411 **Assessment of Messenger RNA of $\beta 1 \rightarrow 4$ -N-Acetylgalactosaminyltransferase as a Molecular Marker for Metastatic Melanoma.** Christine T. Kuo, Peter J. Bostick, Reiko F. Irie, Donald L. Morton, Andrew J. Conrad, and Dave S. B. Hoon.
- 419 **Prognostic Significance of Peripheral Blood and Bone Marrow Tyrosinase Messenger RNA in Malignant Melanoma.** Ronald A. Ghossein, Daniel Coit, Murray Brennan, Zuo Feng Zhang, Yan Wang, Satyajit Bhattacharya, Alan Houghton, and Juan Rosai.
- 429 **Significance of Platelet-derived Endothelial Cell Growth Factor in the Angiogenesis of Human Gastric Cancer.** Yutaka Takahashi, Corazon D. Bucana, Yoshito Akagi, Wenbiao Liu, Karen R. Cleary, Masayoshi Mai, and Lee M. Ellis.
- 435 **Careful Histological Confirmation and Microdissection Reveal Telomerase Activity in Otherwise Telomerase-negative Breast Cancers.** Lisa A. Carey, Catigan A. Hedican, Gregory S. Henderson, Christopher B. Umbricht, Jeffrey S. Dome, Debora Varon, and Saraswati Sukumar.
- 441 **A Comparison between Microsatellite and Quantitative PCR Analyses to Detect Frequent *p16* Copy Number Changes in Primary Bladder Tumors.** John Paul Cairns, Pei-Wen Chiang, Saravanan Ramamoorthy, David M. Kurnit, and David Sidransky.
- 445 **Sequential Treatment of Human Chronic Lymphocytic Leukemia with Bryostatin 1 followed by 2-Chlorodeoxyadenosine: Preclinical Studies.** Ramzi M. Mohammad, Khalil Katato, Victor P. Almatchy, Nathan Wall, Kan-zhi Liu, Christian P. Schultz, Henry H. Mantsch, Mary Varterasian, and Ayad M. Al-Katib.
- 455 **Altered Irinotecan and SN-38 Disposition after Intravenous and Oral Administration of Irinotecan in Mice Bearing Human Neuroblastoma Xenografts.** William C. Zamboni, Peter J. Houghton, Joyce Thompson, Pamela J. Cheshire, Suzan K. Hanna, Lois B. Richmond, Xiaolong Lou, and Clinton F. Stewart.
- 463 **Activity of Fotemustine in Medulloblastoma and Malignant Glioma Xenografts in Relation to *O*⁶-Alkylguanine-DNA Alkyltransferase and Alkylpurine-DNA *N*-Glycosylase Activity.** Gilles Vassal, Isabelle Boland, Marie-José Terrier-Lacombe, Amanda J. Watson, Geoffrey P. Margison, Anne-Marie Vénuat, Jackie Morizet, Fabrice Parker, Catherine Lacroix, Arielle Lellouch-Tubiana, Alain Pierre-Kahn, Marie Gwenaëlle Poullain, and Alain Gouyette.
- 469 **Pretreatment of Colon Carcinoma Cells with Tomudex Enhances 5-Fluorouracil Cytotoxicity.** Giuseppe S. A. Longo, Julie Izzo, Yu Ming Chang, William P. Tong, Zbigniew Zielinski, Richard Gorlick, Ting-Chao Chou, and Joseph R. Bertino.
- 475 **Heterogeneity of *O*⁶-Alkylguanine-DNA-alkyltransferase Measured by Flow Cytometric Analysis in Blood and Bone Marrow Mononuclear Cells.** Lili Liu, Keunmyoung Lee, Jane Schupp, Omer N. Koc, and Stanton L. Gerson.
- 483 **Acute *in Vivo* Resistance in High-Dose Therapy.** Beverly A. Teicher, Gulshan Ara, Susan R. Keyes, Roy S. Herbst, and Emil Frei III.
- 493 **High Susceptibility of Human Cancer Xenografts with Higher Levels of Cytidine Deaminase to a 2'-Deoxycytidine Antimetabolite, 2'-Deoxy-2'-methylidenecytidine.** Masanori Miwa, Hiroyuki Eda, Masako Ura, Kaori F. Ouchi, Dennis D. Keith, Louise H. Foley, and Hideo Ishitsuka.
- 499 **Comparative Study of the Antitumor Activity of Free Doxorubicin and Polyethylene Glycol-coated Liposomal Doxorubicin in a Mouse Lymphoma Model.** Anna Cabanes, Dinah Tzemach, Dorit Goren, Aviva T. Horowitz, and Alberto Gabizon.
- 507 **Phagocytosis of Cross-Linked Gelatin Matrix by Human Breast Carcinoma Cells Correlates with Their Invasive Capacity.** Peter J. Coopman, Michael T. H. Do, Erik W. Thompson, and Susette C. Mueller.
- 517 ***bcl-2*, *bax*, *bcl-x_L*, and *bcl-x_s* Expression in Normal and Neoplastic Ovarian Tissues.** Maria Marone, Giovanni Scambia, Simona Mozzetti, Gabriella Ferrandina, Sonia Iacovella, Anna De Pasqua, Pierluigi Benedetti-Panici, and Salvatore Mancuso.
-
- 525 **AACR Bulletin Board**
Institution of Page Charges
Annual Meeting
Late-Breaking Research Session at the AACR Annual Meeting
Workshop on Molecular Biology in Clinical Oncology
AACR Special Conferences in Cancer Research
- 526 **Author Index**
- i **Instructions for Authors**

1998 AACR Annual Meeting

March 28–April 1, 1998
New Orleans, LA

For complete information about the meeting, visit the AACR Website at

<http://www.aacr.org>

Clinical Cancer Research

4 (2)

Clin Cancer Res 1998;4:265-524.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/4/2.citation>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/4/2.citation>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.